Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction

• Published in: Hepatology research Vol. 48; no. 7; pp. 529 - 538
• Main Authors: Sho, Takuya, Suda, Goki, Nagasaka, Atsushi, Yamamoto, Yoshiya, Furuya, Ken, Kumagai, Kenichi, Uebayashi, Minoru, Terashita, Katsumi, Kobayashi, Tomoe, Tsunematsu, Izumi, Onodera, Manabu, Meguro, Takashi, Kimura, Megumi, Ito, Jun, Umemura, Machiko, Izumi, Takaaki, Kawagishi, Naoki, Ohara, Masatsugu, Ono, Yuji, Nakai, Masato, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya
• Format: Journal Article
• Language: English
• Published: Netherlands Wiley Subscription Services, Inc 01.06.2018
• Subjects: Clinical trials; direct‐acting antiviral; Fibrosis; Genotype & phenotype; Genotypes; Hemoglobin; Hepatitis; Hepatitis C; hepatitis C virus; Liver; Multivariate analysis; Patients; Renal function; renal impairment; Ribavirin; Safety; sofosbuvir; sofosbuvir; hepatitis C virus; direct-acting antiviral; ribavirin; renal impairment

Aim The safety and efficacy of sofosbuvir (SOF) and ribavirin (RBV) have not been well clarified in patients with renal dysfunction because clinical trials have not included such patients. We evaluated the safety and efficacy of SOF and RBV for genotype 2 hepatitis C virus (HCV)‐infected patients wi...